Blow for Novartis as PD-1 drug spartalizumab flunks trialNovartis’ hopes of catching up with other companies in immuno-oncology have been dented after PD-1 inhibitor spartalizumab failed Share XBlow for Novartis as PD-1 drug spartalizumab flunks trialhttps://pharmaphorum.com/news/blow-for-novartis-as-pd-1-drug-spartalizumab-flunks-trial/
